This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| James E. Moore | |
|---|---|
| Name | James E. Moore |
| Birth date | 1940s |
| Birth place | United States |
| Occupation | Academic, researcher, author |
| Known for | Oncology research, surgical oncology, clinical trials |
| Alma mater | Harvard University, Johns Hopkins University |
James E. Moore
James E. Moore is an American surgical oncologist and clinical researcher noted for contributions to oncologic surgery, translational research, and randomized clinical trials. His career spans academic appointments, leadership in multicenter cooperative groups, and authorship of influential studies that intersect surgery, medical oncology, and biostatistics. He has collaborated with institutions and investigators across United States academic medical centers, international research consortia, and professional societies.
Born in the mid-20th century in the United States, Moore completed undergraduate studies at a leading private university before attending medical school at Johns Hopkins University School of Medicine. He undertook general surgery residency training at a major academic hospital associated with Harvard Medical School, followed by fellowship training in surgical oncology and research methodology. During this period he worked alongside faculty affiliated with Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, and the National Cancer Institute, gaining exposure to clinical trials run by the Eastern Cooperative Oncology Group and the American College of Surgeons.
Moore held academic appointments at several tertiary-care medical centers, including professorial roles at institutions connected to Harvard Medical School and regional cancer centers linked to Johns Hopkins University. He served as director of surgical oncology programs at university hospitals and was a principal investigator for cooperative-group trials coordinated by the National Surgical Adjuvant Breast and Bowel Project and the North Central Cancer Treatment Group. Moore participated in guideline development with panels convened by the American Society of Clinical Oncology and the Society of Surgical Oncology, and he collaborated with leaders from European Society for Medical Oncology and Union for International Cancer Control in multinational initiatives. Administrative roles included membership on institutional review boards at centers affiliated with Massachusetts General Hospital and advisory positions with the National Institutes of Health.
Moore’s research portfolio combines clinical trials, translational studies, and methodological work. He published randomized trials comparing surgical techniques and adjuvant therapies with coauthors from Memorial Sloan Kettering Cancer Center, Mayo Clinic, MD Anderson Cancer Center, and Fred Hutchinson Cancer Research Center. His studies addressed outcomes in colorectal, breast, and hepatopancreatobiliary oncology and were reported in journals read by clinicians at New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, and specialty periodicals associated with the American College of Surgeons and European Journal of Surgical Oncology. Collaborations included biostatisticians from Harvard School of Public Health and molecular investigators from Cold Spring Harbor Laboratory and Broad Institute to integrate biomarker assays into trial designs.
Moore contributed to guidelines and consensus statements on perioperative management and trial endpoints in partnership with panels convened by American Society of Clinical Oncology, Society of Surgical Oncology, and the National Comprehensive Cancer Network. He authored book chapters in surgical oncology texts published by academic presses used at Johns Hopkins University and Oxford University Press-affiliated titles, and he lectured at conferences organized by American Association for Cancer Research, European Society for Medical Oncology, and regional meetings of the Society of Surgical Oncology. His methodological publications addressed randomized trial design, quality-of-life endpoints endorsed by the Food and Drug Administration, and multi-institutional data harmonization efforts coordinated with the Clinical Trials Transformation Initiative.
Throughout his career Moore received recognition from surgical and oncology societies. Honors included lifetime achievement citations from the Society of Surgical Oncology and distinguished investigator awards from the American Association for Cancer Research and the American College of Surgeons. He received invited fellowships and visiting professorships at centers such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Royal Marsden Hospital, and was elected to leadership roles within the American Society of Clinical Oncology and regional academies of medicine. Moore’s work was acknowledged in citations by funding bodies including the National Cancer Institute and private foundations affiliated with the American Cancer Society.
Outside clinical work, Moore maintained collaborations with philanthropic and patient advocacy organizations like the American Cancer Society and the Susan G. Komen Foundation, supporting translational research and clinical trial access. He mentored generations of surgeons and oncologists who went on to faculty positions at Harvard Medical School, Johns Hopkins University, Mayo Clinic, and international centers including Royal Marsden Hospital and Institut Gustave Roussy. His legacy is reflected in the adoption of evidence-based surgical practices, the integration of biomarkers into perioperative trials, and the formation of durable cooperative networks among institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Fred Hutchinson Cancer Research Center, and the National Cancer Institute.